Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Receivables (2016 - 2025)

STRATA Skin Sciences (SSKN) has disclosed Receivables for 14 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 21.55% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, down 21.55% year-over-year, with the annual reading at $4.1 million for FY2025, 21.55% down from the prior year.
  • Receivables hit $4.1 million in Q4 2025 for STRATA Skin Sciences, up from $3.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $5.3 million in Q4 2024 to a low of $2.9 million in Q1 2021.
  • Historically, Receivables has averaged $3.9 million across 5 years, with a median of $3.9 million in 2023.
  • Biggest five-year swings in Receivables: surged 109.7% in 2021 and later dropped 21.55% in 2025.
  • Year by year, Receivables stood at $3.4 million in 2021, then soared by 30.24% to $4.5 million in 2022, then dropped by 0.69% to $4.4 million in 2023, then increased by 18.31% to $5.3 million in 2024, then decreased by 21.55% to $4.1 million in 2025.
  • Business Quant data shows Receivables for SSKN at $4.1 million in Q4 2025, $3.5 million in Q3 2025, and $4.0 million in Q2 2025.